Hassan A Aziz1, Jonathan W Kim1, Francis L Munier2, Jesse L Berry1. 1. The Vision Center at Children's Hospital Los Angeles, USC Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, Calif., USA. 2. Department of Ophthalmology, Jules Gonin Eye Hospital, Lausanne, Switzerland.
Abstract
AIMS: To report the occurrence of acute hemorrhagic retinopathy following intravitreal melphalan injection for retinoblastoma. METHODS: This is a retrospective case series of 2 patients with retinoblastoma treated with intravitreal melphalan for vitreous seeding who developed acute hemorrhagic retinopathy. RESULTS: Patient 1 is a 6-month-old female with bilateral retinoblastoma (Group D right eye and Group B left eye) treated with 4 cycles of systemic chemotherapy and 2 intravitreal melphalan injections in each eye. Patient 2 is a 10-month-old male with unilateral Group D retinoblastoma treated with 6 cycles of systemic chemotherapy and 2 injections of intravitreal melphalan. At the 1-week follow-up after the second injection, both patients had an acute hemorrhagic retinopathy that resulted in chorioretinal toxicity with a sharp demarcation line between the normal and abnormal retina. At the last follow-up (22 and 12 months, respectively), there was total tumor control and resolution of vitreous seeding in both patients. CONCLUSIONS: Although intravitreal melphalan injection is effective for vitreous seeding in eyes with retinoblastoma, acute hemorrhagic retinopathy and diffuse chorioretinal atrophy is a possible complication of this treatment modality. Given the clinical findings observed in these patients, the development of this retinal toxicity most likely results from a retrohyaloid overdose. Consequently we suggest preventive measures aimed at limiting the risk of retrohyaloid injection.
AIMS: To report the occurrence of acute hemorrhagic retinopathy following intravitreal melphalan injection for retinoblastoma. METHODS: This is a retrospective case series of 2 patients with retinoblastoma treated with intravitreal melphalan for vitreous seeding who developed acute hemorrhagic retinopathy. RESULTS:Patient 1 is a 6-month-old female with bilateral retinoblastoma (Group D right eye and Group B left eye) treated with 4 cycles of systemic chemotherapy and 2 intravitreal melphalan injections in each eye. Patient 2 is a 10-month-old male with unilateral Group D retinoblastoma treated with 6 cycles of systemic chemotherapy and 2 injections of intravitreal melphalan. At the 1-week follow-up after the second injection, both patients had an acute hemorrhagic retinopathy that resulted in chorioretinal toxicity with a sharp demarcation line between the normal and abnormal retina. At the last follow-up (22 and 12 months, respectively), there was total tumor control and resolution of vitreous seeding in both patients. CONCLUSIONS: Although intravitreal melphalan injection is effective for vitreous seeding in eyes with retinoblastoma, acute hemorrhagic retinopathy and diffuse chorioretinal atrophy is a possible complication of this treatment modality. Given the clinical findings observed in these patients, the development of this retinal toxicity most likely results from a retrohyaloid overdose. Consequently we suggest preventive measures aimed at limiting the risk of retrohyaloid injection.
Authors: Heather A Hancock; Clyde Guidry; Russell W Read; Edgar L Ready; Timothy W Kraft Journal: Invest Ophthalmol Vis Sci Date: 2005-12 Impact factor: 4.799
Authors: Fernando Marcondes Penha; Eduardo B Rodrigues; Maurício Maia; Bruno A Furlani; Caio Regatieri; Gustavo B Melo; Octaviano Magalhães; Roberta Manzano; Michel E Farah Journal: Ophthalmic Res Date: 2010-08-10 Impact factor: 2.892
Authors: Jasmine H Francis; Paula Schaiquevich; Emiliano Buitrago; María José Del Sole; Gustavo Zapata; J Oscar Croxatto; Brian P Marr; Scott E Brodie; Alejandro Berra; Guillermo L Chantada; David H Abramson Journal: Ophthalmology Date: 2014-05-10 Impact factor: 12.079
Authors: Ramsudha Narala; Jonathan W Kim; Paul Lang; Bao Han A Le; Hansford C Hendargo; Dorothy Branco; Jesse L Berry Journal: Ophthalmol Retina Date: 2018-10-05
Authors: M J Del Sole; M Clausse; P Nejamkin; B Cancela; M Del Río; G Lamas; F Lubieniecki; J H Francis; D H Abramson; G Chantada; P Schaiquevich Journal: Exp Eye Res Date: 2022-03-08 Impact factor: 3.770
Authors: Carley M Bogan; Jessica V Kaczmarek; Janene M Pierce; Sheau-Chiann Chen; Kelli L Boyd; Marion W Calcutt; Thomas M Bridges; Craig W Lindsley; Jennifer B Nadelmann; Albert Liao; Terry Hsieh; David H Abramson; Jasmine H Francis; Debra L Friedman; Ann Richmond; Anthony B Daniels Journal: Br J Ophthalmol Date: 2021-05-10 Impact factor: 4.638